# Richard Kefford

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-kefford/

## Facts

| Field | Value |
| --- | --- |
| Citations | 95,033 |
| Field | Melanoma and MAPK Pathways |
| h-index | 123 |
| i10-index | 364 |
| Last Known Institution | Broad Institute |
| OpenAlex ID | https://openalex.org/A5062978331 |
| ORCID iD | https://orcid.org/0000-0001-9251-9229 |
| Works | 602 |

## Researcher papers

- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Broad Institute](https://scholariq.org/institutions/broad-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.